3-peptide research blend in one vial: Tesamorelin + CJC-1295 without DAC + Ipamorelin. A triple GH stack combining two GHRH analogs — Tesamorelin (a stabilized GHRH, FDA-approved standalone for HIV-associated lipodystrophy) and CJC-1295 — with the selective GHRP Ipamorelin.
A blend has one whole-vial purity, but the number that decides what you're holding is the net content of each component — an HPLC run resolves a separate peak for each. So we verify Tesamorelin + CJC-1295 + Ipamorelin component by component. Each links to its own compound page, where its full independent testing lives.
| Component | Typical mg | Role in the blend | Verified purity | |
|---|---|---|---|---|
| Tesamorelin | varies | Stabilised GHRH analog — amplitude; FDA-approved standalone | 99.4% · 543 tests | View testing → |
| CJC-1295 without DAC | varies | GHRH analog — raises GH pulse amplitude | 99.5% · 296 tests | View testing → |
| Ipamorelin | varies | Most selective GHRP — minimal cortisol, prolactin or hunger | 99.7% · 439 tests | View testing → |
Composition varies by vendor. The components above are consistent across shops, but the milligrams and ratio are not — always dose by the individual component amounts printed on your vial, never by a generic “blend dose.”
A blend is the single hardest product to trust — the whole-vial purity tells you the material is clean, but not whether every peptide is present in the right amount. Two questions decide that, and both are answerable in a lab.
Mass spec (or a clean HPLC peak per compound) confirms each peptide is in the vial — not one short, not a cheaper substitute standing in for the expensive one.
Tested milligrams vs. labelled milligrams, per component. This is where blends fail quietly — one component underdosed to pad margin while the vial still “contains” everything.
Tests run on a Tesamorelin + CJC-1295 + Ipamorelin vial as sold — broken down per component. This is the data no shop and no competitor publishes.
| Component | Labelled | Net content (tested) | Identity (LC-MS) | Vs. label |
|---|---|---|---|---|
| Tesamorelin | 6 mg | 6 mg | ✓ present | Within (+0%) |
| CJC-1295 without DAC | 3 mg | 3 mg | ✓ present | Within (+0%) |
| Ipamorelin | 3 mg | 3 mg | ✓ present | Within (+0%) |
Until more Tesamorelin + CJC-1295 + Ipamorelin vials are tested, the strongest signal is how each component performs in single-compound testing across the shops we track. Tap any card for its full data.
Last Updated: August 2026
Last Updated: August 2026
This triple stack combines two GHRH analogs — Tesamorelin (a stabilized GHRH, notably the one component here that is FDA-approved as a standalone drug, Egrifta, for HIV-associated lipodystrophy) and CJC-1295 (without DAC) — with the selective GHRP Ipamorelin. As a stack this combination is not an approved product and is research-use-only. Tesamorelin's only approved form is the prescription drug Egrifta (HIV-associated lipodystrophy); the research-grade tesamorelin sold in blends is not that product. CJC-1295 has no compounding pathway — the FDA's Pharmacy Compounding Advisory Committee reviewed CJC-1295 in December 2024 and recommended against adding it to the 503A bulk-substances list ("do not include"). Ipamorelin acetate remains in Category 2 of the FDA's bulk-drug-substances evaluation (the 503B outsourcing-facility route) and was not among the twelve peptides removed from Category 2 in April 2026. In sport, all three are prohibited at all times by the World Anti-Doping Agency under Section S2.2.4 (growth-hormone-releasing factors and secretagogues), as of August 2026.
The stack pairs the GHRH amplitude side (using two GHRH analogs — Tesamorelin, valued for its lipodystrophy/visceral-fat data, plus CJC-1295) with the frequency/somatostatin-suppression side from the selective, clean GHRP Ipamorelin; the rationale is a strong GH stimulus with a favorable side-effect profile (Ipamorelin's selectivity). No controlled clinical trial of the Tesamorelin + CJC-1295 + Ipamorelin blend has been published as of August 2026; layering two GHRH-side analogs onto a ghrelin mimetic adds redundancy and more variables, and the case for it is a mechanistic rationale, not a clinically-validated combined outcome.
The combination is not an approved product and is research-use-only; verify each labeled component's identity and purity via HPLC and mass-spec. Peptigrity collects independent third-party Certificates of Analysis for Tesamorelin + CJC-1295 + Ipamorelin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The shop trust score weights lab purity and reviews equally (50/50). See how to read lab results.
Educational information only; not medical advice. This is a research-use-only stack, not an approved therapy. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.
In a blend you can only set the dose of one component — the rest follow the fixed ratio. Our calculator does that math so you don't underdose the peptide you actually care about.
Enter each component's milligrams and your BAC water — get per-component units for one syringe draw.
Open the blend calculator →How much bacteriostatic water, mixing without shaking, storage, and shelf life once mixed.
Read the reconstitution guide →Tesamorelin is FDA-approved on its own (as Egrifta) for HIV-associated lipodystrophy — but this three-peptide combination is not an approved product.
The stack layers Tesamorelin and CJC-1295 on the amplitude side plus Ipamorelin on the frequency side — though two GHRH analogs adds redundancy and more variables.
The combination is not an approved product; sold as a stack it is RUO, and these components are banned in sport (WADA). Verify local rules.
No. Peptigrity is an independent review platform, not a medical authority.